Zobrazeno 1 - 10
of 1 379
pro vyhledávání: '"Nola M"'
Autor:
Wen Li, Nu N. Le, Rohan Nadkarni, Natsuko Onishi, Lisa J. Wilmes, Jessica E. Gibbs, Elissa R. Price, Bonnie N. Joe, Rita A. Mukhtar, Efstathios D. Gennatas, John Kornak, Mark Jesus M. Magbanua, Laura J. van’t Veer, Barbara LeStage, Laura J. Esserman, Nola M. Hylton
Publikováno v:
Tomography, Vol 10, Iss 11, Pp 1832-1845 (2024)
Background: This multicenter and retrospective study investigated the additive value of tumor morphologic features derived from the functional tumor volume (FTV) tumor mask at pre-treatment (T0) and the early treatment time point (T1) in the predicti
Externí odkaz:
https://doaj.org/article/239e5715cc2941a296c96473b259310b
Autor:
Julie E. Lang, Andres Forero-Torres, Douglas Yee, Christina Yau, Denise Wolf, John Park, Barbara A. Parker, A. Jo Chien, Anne M. Wallace, Rashmi Murthy, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Rachel L. Yung, Claudine Isaacs, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Erica Stringer-Reasor, Elissa Price, Bonnie Joe, Minetta C. Liu, Lamorna Brown-Swigart, Emanuel F. Petricoin, Julia D. Wulfkuhle, Meredith Buxton, Julia L. Clennell, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van ‘t Veer, Nola M. Hylton, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract HSP90 inhibitors destabilize oncoproteins associated with cell cycle, angiogenesis, RAS-MAPK activity, histone modification, kinases and growth factors. We evaluated the HSP90-inhibitor ganetespib in combination with standard chemotherapy in
Externí odkaz:
https://doaj.org/article/f1ec1969e2aa401dafdcc1102c26a20e
Autor:
Rhea Chitalia, Sarthak Pati, Megh Bhalerao, Siddhesh Pravin Thakur, Nariman Jahani, Vivian Belenky, Elizabeth S. McDonald, Jessica Gibbs, David C. Newitt, Nola M. Hylton, Despina Kontos, Spyridon Bakas
Publikováno v:
Scientific Data, Vol 9, Iss 1, Pp 1-7 (2022)
Abstract Breast cancer is one of the most pervasive forms of cancer and its inherent intra- and inter-tumor heterogeneity contributes towards its poor prognosis. Multiple studies have reported results from either private institutional data or publicl
Externí odkaz:
https://doaj.org/article/ad25578784834782a0b3e405eb4c6a75
Autor:
Nu N. Le, Wen Li, Natsuko Onishi, David C. Newitt, Jessica E. Gibbs, Lisa J. Wilmes, John Kornak, Savannah C. Partridge, Barbara LeStage, Elissa R. Price, Bonnie N. Joe, Laura J. Esserman, Nola M. Hylton
Publikováno v:
Tomography, Vol 8, Iss 3, Pp 1208-1220 (2022)
This study evaluated the inter-reader agreement of tumor apparent diffusion coefficient (ADC) measurements performed on breast diffusion-weighted imaging (DWI) for assessing treatment response in a multi-center clinical trial of neoadjuvant chemother
Externí odkaz:
https://doaj.org/article/4e753dc001e14a2996cd0448e63b5a67
Publikováno v:
BMC Medical Ethics, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Defensive practice occurs when physicians provide services, such as tests, treatments and referrals, mainly to reduce their perceived legal or reputational risks, rather than to advance patient care. This behaviour is counter to p
Externí odkaz:
https://doaj.org/article/b909667a1f90439cbc972907f7102033
Autor:
Savannah C. Partridge, Jon Steingrimsson, David C. Newitt, Jessica E. Gibbs, Helga S. Marques, Patrick J. Bolan, Michael A. Boss, Thomas L. Chenevert, Mark A. Rosen, Nola M. Hylton
Publikováno v:
Tomography, Vol 8, Iss 2, Pp 701-717 (2022)
In diffusion-weighted MRI (DW-MRI), choice of b-value influences apparent diffusion coefficient (ADC) values by probing different aspects of the tissue microenvironment. As a secondary analysis of the multicenter ECOG-ACRIN A6698 trial, the purpose o
Externí odkaz:
https://doaj.org/article/5c5a779cb97d4e7db7ebdf78c0bc4d92
Autor:
Alex Anh-Tu Nguyen, Natsuko Onishi, Julia Carmona-Bozo, Wen Li, John Kornak, David C. Newitt, Nola M. Hylton
Publikováno v:
Tomography, Vol 8, Iss 2, Pp 891-904 (2022)
Background parenchymal enhancement (BPE) of breast fibroglandular tissue (FGT) in dynamic contrast-enhanced breast magnetic resonance imaging (MRI) has shown an association with response to neoadjuvant chemotherapy (NAC) in patients with breast cance
Externí odkaz:
https://doaj.org/article/f0fb61a245944c9989f5a93fdfa7d19a
Publikováno v:
Health Expectations, Vol 25, Iss 1, Pp 374-383 (2022)
Abstract Background The patient–clinician interaction is a site at which defensive practice could occur, when clinicians provide tests, procedures and treatments mainly to reduce perceived legal risks, rather than to advance patient care. Defensive
Externí odkaz:
https://doaj.org/article/88d88c4de335491c892715880468fbc3
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8